{"id":62428,"date":"2026-01-01T13:05:53","date_gmt":"2026-01-01T12:05:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/"},"modified":"2026-01-01T13:05:53","modified_gmt":"2026-01-01T12:05:53","slug":"7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/","title":{"rendered":"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/6214890\/diabetic-macular-edema-dme-epidemiology?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=d4vpvm&amp;utm_campaign=2125101+-+7MM+Diabetic+Macular+Edema+(DME)+Epidemiology+Forecast+Report+2024-2034%3A+Focus+on+US%2C+France%2C+Germany%2C+Italy%2C+Spain%2C+UK%2C+and+Japan&amp;utm_exec=chdomspi\" rel=\"nofollow\" shape=\"rect\">&#8220;Diabetic Macular Edema (DME): Epidemiology Forecast to 2034&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/22\/logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/21\/logo.jpg\"><\/a><\/p>\n<p>\nIn the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 cases in 2024 to 3,463,149 cases in 2034, at an annual growth rate (AGR) of 1.99%.<\/p>\n<p>\nIn 2034, the US will have the highest number of diagnosed prevalent cases of DME in diabetes in the 7MM, with 1,012,428 cases, whereas Japan will have the fewest diagnosed prevalent cases of DME in diabetes with 125,490 cases. The analyst epidemiologists attribute the change in the diagnosed prevalent cases of DME in diabetes to changing prevalence trends in the 7MM and the changes in population dynamics in each market over the forecast period.<\/p>\n<p>\n<strong>Report Scope<\/strong><\/p>\n<ul>\n<li>\nThis report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).<\/li>\n<li>\nThe report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of DME in diabetes. The diagnosed prevalent cases of DME are segmented by sex and age (ages 20 years and older) in these markets.<\/li>\n<li>\nThe diagnosed prevalent cases of DME are further segmented by involvement of the eye by center involving DME (ci-DME), and non-center involving (nci-DME). This epidemiology forecast for DME is supported by data obtained from peer-reviewed articles and population-based studies.<\/li>\n<li>\nThe forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the diagnosed prevalent cases of DME across these markets.<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong><\/p>\n<p>\n<strong>1 Diabetic Macular Edema: Executive Summary<\/strong><\/p>\n<p>\n1.1 Catalyst<\/p>\n<p>\n1.2 Related reports<\/p>\n<p>\n1.3 Upcoming reports<\/p>\n<p>\n<strong>2 Epidemiology<\/strong><\/p>\n<p>\n2.1 Disease background<\/p>\n<p>\n2.2 Risk factors and comorbidities<\/p>\n<p>\n2.3 Global and historical trends<\/p>\n<p>\n2.4 7MM forecast methodology<\/p>\n<p>\n2.4.1 Sources<\/p>\n<p>\n2.4.2 Forecast assumptions and methods<\/p>\n<p>\n2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of DME in diabetes &#8211; 7MM<\/p>\n<p>\n2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of DME by involvement of the eye<\/p>\n<p>\n2.5 Epidemiological forecast for DME (2024-34)<\/p>\n<p>\n2.5.1 Diagnosed prevalent cases of DME in diabetes<\/p>\n<p>\n2.5.2 Age-specific diagnosed prevalent cases of DME in diabetes<\/p>\n<p>\n2.5.3 Sex-specific diagnosed prevalent cases of DME in diabetes<\/p>\n<p>\n2.5.4 Diagnosed prevalent cases of DME by involvement of the eye<\/p>\n<p>\n2.6 Discussion<\/p>\n<p>\n2.6.1 Epidemiological forecast insight<\/p>\n<p>\n2.6.2 Limitations of the analysis<\/p>\n<p>\n2.6.3 Strengths of the analysis<\/p>\n<p>\n<strong>3 Appendix<\/strong><\/p>\n<p>\n3.1 Bibliography<\/p>\n<p>\n3.2 About the authors<\/p>\n<p>\n3.2.1 Epidemiologist<\/p>\n<p>\n3.2.2 Reviewers<\/p>\n<p>\n3.2.3 Vice President of Disease Intelligence and Epidemiology<\/p>\n<p>\n3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence<\/p>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/6214890\/diabetic-macular-edema-dme-epidemiology?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=d4vpvm&amp;utm_campaign=2125101+-+7MM+Diabetic+Macular+Edema+(DME)+Epidemiology+Forecast+Report+2024-2034%3A+Focus+on+US%2C+France%2C+Germany%2C+Italy%2C+Spain%2C+UK%2C+and+Japan&amp;utm_exec=chdomspi\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/5p24qq<\/a><\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong><\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"mai&#108;&#116;&#111;&#x3a;&#x70;&#x72;&#x65;&#x73;&#x73;&#64;re&#115;&#101;&#97;&#114;&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;ark&#101;&#116;&#115;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x70;&#x72;&#101;&#115;s&#x40;&#x72;&#x65;&#115;&#101;a&#x72;&#x63;&#x68;&#97;&#110;d&#x6d;&#x61;&#x72;&#107;&#101;t&#x73;&#x2e;&#x63;&#111;m<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Diabetic Macular Edema (DME): Epidemiology Forecast to 2034&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 cases in 2024 to 3,463,149 cases in 2034, at an annual growth rate (AGR) of 1.99%. In 2034, the US will &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62428","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Diabetic Macular Edema (DME): Epidemiology Forecast to 2034&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 cases in 2024 to 3,463,149 cases in 2034, at an annual growth rate (AGR) of 1.99%. In 2034, the US will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-01T12:05:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/22\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2026-01-01T12:05:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260101650213\\\/en\\\/2680401\\\/22\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/\",\"name\":\"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260101650213\\\/en\\\/2680401\\\/22\\\/logo.jpg\",\"datePublished\":\"2026-01-01T12:05:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260101650213\\\/en\\\/2680401\\\/22\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260101650213\\\/en\\\/2680401\\\/22\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Diabetic Macular Edema (DME): Epidemiology Forecast to 2034&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 cases in 2024 to 3,463,149 cases in 2034, at an annual growth rate (AGR) of 1.99%. In 2034, the US will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-01T12:05:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/22\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan &#8211; ResearchAndMarkets.com","datePublished":"2026-01-01T12:05:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/"},"wordCount":502,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/22\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/","name":"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/22\/logo.jpg","datePublished":"2026-01-01T12:05:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/22\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260101650213\/en\/2680401\/22\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/7mm-diabetic-macular-edema-dme-epidemiology-forecast-report-2024-2034-focus-on-us-france-germany-italy-spain-uk-and-japan-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62428"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62428\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}